CS10BR05 / CoreStem - LARVOL DELTA

Long-term Follow-up of Phase 1 Clinical Trial of CS10BR05(CS10BR05-MSA101) (clinicaltrials.gov) - P=N/A | N=8 | Completed | Sponsor: Corestemchemon, Inc. | Active, not recruiting ➔ Completed

Trial completion • CNS Disorders • Movement Disorders • Multiple System Atrophy

Safety and Tolerability of CS10BR05 Inj. in Subjects With Multiple System Atrophy (clinicaltrials.gov) - P1; N=9; Completed; Sponsor: Corestem, Inc.; Active, not recruiting ➔ Completed; Trial completion date: Apr 2020 ➔ Dec 2019

Clinical • Trial completion • Trial completion date • CNS Disorders • Movement Disorders • Multiple System Atrophy

Long-term Follow-up of Phase 1 Clinical Trial of CS10BR05(CS10BR05-MSA101) (clinicaltrials.gov) - P; N=8; Active, not recruiting; Sponsor: Corestem, Inc.

Clinical • New trial • CNS Disorders • Movement Disorders • Multiple System Atrophy • CST3

Safety and Tolerability of CS10BR05 Inj. in Subjects With Multiple System Atrophy (clinicaltrials.gov) - P1; N=9; Active, not recruiting; Sponsor: Corestem, Inc.; Recruiting ➔ Active, not recruiting; Trial completion date: Dec 2018 ➔ Apr 2020

Enrollment closed • Trial completion date